PMID- 25360835
OWN - NLM
STAT- MEDLINE
DCOM- 20160517
LR  - 20191027
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 13
IP  - 4
DP  - 2015
TI  - Combination Therapy with Chinese Medicine and ACEI/ARB for the Management of 
      Diabetic Nephropathy: The Promise in Research Fragments.
PG  - 526-39
AB  - BACKGROUND: The clinical benefits of the application of renin-angiotensin system 
      (RAS) blockade, i.e., angiotensin-converting enzyme inhibitors (ACEI) or 
      angiotensin receptor blockers (ARB), have been well established in patients with 
      diabetic nephropathies (DN). Since the combination therapy with Chinese Medicine 
      (CM) and conventional western medicine (CWM) is considered an effective approach 
      to many conditions, many CM experts have investigated the combination therapy 
      with CM and RAS blockade to look for new approaches to DN. AIM: The purpose of 
      this article is to review the antiproteinuric and renopretective effects of 
      combination therapy of CM and ACEI/ARBs for the management of DN. METHODS: 
      Relevant articles were identified through PubMed and three major Chinese 
      databases (CBM, CAJD, CSTJ) up to March 2013. FINDINGS: The results of the 
      current literature are consistent with CM theories (e.g., tonifying and 
      replenishing CM with blood-activating and stasis-resolving CM as major 
      therapeutic strategies for the management of DN). 91 clinical articles on the 
      combination therapy of CM and ACEI/ARBs were identified, but only eight 
      randomized controlled trials were eventually included in the present review. The 
      results were not always consistent: three articles reported that CM conferred 
      both anti-proteinuric and reno-protective effects in addition to ACEI/ARBs; three 
      articles reported that CM failed to provide additional reno-protective benefits; 
      two articles reported that CM conferred neither anti-proteinuric nor 
      renoprotective effects in addition to ACEI/ARBs. CONCLUSION: Current literature 
      indicates that combination therapy with CM and ACEI/ARBs might have 
      polypharmacological anti-proteinuric and reno-protective effects for the 
      management of DN. Shortcomings concerning the interaction between CM and CWM, 
      methodology, and study design need to be addressed in future research.
FAU - Tu, Xiang
AU  - Tu X
FAU - Ye, XueFeng
AU  - Ye X
FAU - Xie, ChunGuang
AU  - Xie C
FAU - Chen, Jing
AU  - Chen J
FAU - Wang, Fei
AU  - Wang F
FAU - Zhong, Sen
AU  - Zhong S
AD  - Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 
      610072, Sichuan Province, China. zhongsen6606@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Angiotensin Receptor Antagonists/administration & dosage/*therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Diabetic Nephropathies/*drug therapy
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Humans
MH  - Medicine, Chinese Traditional/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2014/11/02 06:00
MHDA- 2016/05/18 06:00
CRDT- 2014/11/01 06:00
PHST- 2014/03/31 00:00 [received]
PHST- 2014/04/29 00:00 [revised]
PHST- 2014/05/21 00:00 [accepted]
PHST- 2014/11/01 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
AID - CVP-EPUB-62842 [pii]
AID - 10.2174/1570161112666141014153410 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2015;13(4):526-39. doi: 10.2174/1570161112666141014153410.